What is it about?
Metabolic syndrome (MetS) is a group of several metabolic abnormalities such as abdominal obesity, dyslipidemia, hyperglycemia, insulin resistance, and high blood pressure.The chronic low-grade inflammation is a distinctive characteristic of metabolic syndrome. As the Monocyte Chemoattractant Protein-1 (MCP-1) is a biomarker for inflammation indication, we found the interrelation between MCP-1 and the MetS clinical characteristics in order to use it asa diagnostic marker for MetS sevirity prediction in early period of the syndrome.
Featured Image
Why is it important?
According to International Diabetes Federation (IDF) patients, with metabolic syndrome at high risk of development of cardiovascular disease, type 2 diabetes mellitus, atherosclerosis, and all that are major cause of mortality among populations so the early dignosis for the syndrome is very important using the Monocyte Chemoattractant Protein-1 (MCP-1) as inflammation biomarker.
Perspectives
The work in this research article was a challenge du to the incident of articles and researches that discuss the general health issue which related to metabolic and overweight disease and the classical diagnostic criteria which lead us as a researchers to investigated about the unknown substantial causes of this disease clusters and we hope this investigation will helps to offer for the health practitioners a new diagnostic concepts.
Shumoos Alwaid
Read the Original
This page is a summary of: Study the interrelation between monocyte chemoattractant protein-1 (MCP-1) with clinical characteristics of metabolic syndrome patients, January 2022, American Institute of Physics,
DOI: 10.1063/5.0067221.
You can read the full text:
Contributors
The following have contributed to this page
